Core Insights - Valneva reported total product sales of EUR 157.9 million for the year, a decrease of 3.3% year over year, attributed mainly to a planned reduction in third-party product sales and adverse currency impacts [1][5] - The company achieved total revenues exceeding EUR 170 million in 2025, with a cash position of nearly EUR 110 million and a more than 20% reduction in operating cash burn [2][5] - The upcoming phase 3 data for the Lyme disease vaccine candidate VLA15, partnered with Pfizer, is highlighted as a significant near-term value driver [3][6] Financial Performance - Valneva's total revenues for 2025 were reported at over EUR 170 million, with product sales around EUR 158 million and an operating loss of EUR 82.1 million [5][21] - The company guided for 2026 product sales between EUR 145 million and EUR 160 million, and total revenues of EUR 155 million to EUR 170 million, indicating a forecasted decline mainly due to planned cuts in third-party sales [5][22] - Operating cash burn was reduced by over 20%, reflecting disciplined cash management [2][5] Product and Pipeline Highlights - IXIARO sales grew to EUR 98.4 million, a 4.6% increase year over year, while IXCHIQ reached EUR 8.4 million, driven by a pilot campaign in Brazil [4][9] - Third-party product sales fell to EUR 19.2 million, down from EUR 33.2 million, due to the termination of distribution contracts [4][9] - The Lyme disease vaccine VLA15 is undergoing a pivotal phase 3 trial with results expected in the first half of 2026 [6][10] Research and Development - R&D expenses increased to EUR 85.3 million, driven by higher spending on the phase 2 Shigella program and increased investment in IXCHIQ [20] - The company is also focusing on the chikungunya vaccine IXCHIQ, with a pilot vaccination campaign initiated in Brazil [15][16] - Progress is being made on the Shigella candidate S4V2, with ongoing phase 2 studies and data expected around mid-2026 [17] Strategic Outlook - Management emphasized a focus on self-sustainability, particularly if the Lyme vaccine is approved, aiming for potential profitability [22] - The company is refining its commercial strategy and expanding partnerships for its vaccine portfolio, particularly in low- and middle-income countries [15][16]

Financial Data and Key Metrics Changes - Total revenues exceeded EUR 170 million, slightly above 2024 levels, with almost EUR 160 million in product sales [4] - Operating cash burn reduced by over 20%, driven by disciplined cash management [5] - Loss for the period reached EUR 115.2 million, with an adjusted EBITDA reported at -EUR 51.4 million [20] Business Line Data and Key Metrics Changes - Total product sales reached EUR 157.9 million, decreasing by 3.3% over 2024, primarily due to planned reduction in third-party sales [15] - IXIARO sales grew to EUR 98.4 million, representing a growth of 4.6% [15] - IXCHIQ sales increased to EUR 8.4 million from EUR 3.7 million in the prior year [16] Market Data and Key Metrics Changes - Proprietary product sales, excluding currency effects, grew by 9% year-over-year [15] - Third-party sales decreased significantly from EUR 33.2 million to EUR 19.2 million due to the termination of distribution contracts [16] Company Strategy and Development Direction - The company aims to become a leading vaccine biotech company by growing its commercial business and optimizing cash generation [6] - Plans to enhance the R&D pipeline with a focus on vector-borne diseases and expanding beyond this area [23] - Strategic in-licensing to augment the pipeline and create a risk-balanced portfolio of innovative vaccine assets [23] Management's Comments on Operating Environment and Future Outlook - Management highlighted resilience in a year marked by geopolitical uncertainty and rising vaccine hesitancy [4] - Positive phase 3 results for the Lyme disease vaccine candidate could be transformational, delivering substantial revenue [22] - The company expects total product sales in 2026 to be between EUR 145 million and EUR 160 million, with a focus on reducing operating cash burn [20] Other Important Information - The company closed the year with a cash position of nearly EUR 110 million and enhanced financial flexibility through successful debt refinancing [4] - The Lyme disease vaccine candidate, VLA15, is currently in a pivotal phase 3 study with results expected in the first half of 2026 [6][9] Q&A Session Summary Question: What is the expected timeline for the Lyme data readout? - Management indicated that Pfizer controls the study execution and expects data around mid of H1 2026 [27] Question: What gives confidence in VLA15's efficacy across different serotypes? - Management noted preclinical models showed promising results, but human data is still needed to confirm efficacy across serotypes [30] Question: How will capital allocation change if Lyme is successful? - Management stated that positive phase 3 data would not yield immediate milestones, with commercial sales milestones expected later [34] Question: What is the status of the DoD contract for IXIARO? - Management confirmed that a new contract is expected this year, and current shipments continue under the existing contract [46][58] Question: What are the next steps for the chikungunya vaccine VLA1553? - Management expects approval from Anvisa soon and is evaluating commercialization strategies in Asia [62][64]

Financial Data and Key Metrics Changes - Total revenues for Valneva exceeded EUR 170 million, slightly above 2024 levels, with nearly EUR 160 million in product sales [4] - Operating loss reached EUR 82.1 million compared to an operating profit of EUR 13.3 million in 2024, primarily due to non-recurring income from the sale of a priority review voucher in the previous year [20] - The company reported a loss for the period of EUR 115.2 million, with adjusted EBITDA at -EUR 51.4 million [20] Business Line Data and Key Metrics Changes - Total product sales reached EUR 157.9 million, decreasing by 3.3% over 2024, primarily due to planned reductions in third-party sales [15] - IXIARO sales grew to EUR 98.4 million, a 4.6% increase from EUR 94.1 million in 2024, driven by the travel segment [15] - IXCHIQ sales increased significantly to EUR 8.4 million from EUR 3.7 million in the prior year, including the supply of 40,000 doses to La Réunion [16] Market Data and Key Metrics Changes - The company noted a significant reduction in third-party sales from EUR 33.2 million to EUR 19.2 million due to the termination of distribution contracts [16] - Other revenues increased from EUR 6.3 million to EUR 16.8 million, driven by a EUR 10 million revenue recognition related to a license agreement with Pfizer [17] Company Strategy and Development Direction - Valneva aims to become a leading vaccine biotech company by focusing on growing its commercial business and optimizing cash generation [5] - The company is advancing its Lyme disease vaccine candidate, VLA15, which represents a significant opportunity in an underserved market [6] - Valneva plans to expand beyond vector-borne diseases and is exploring in-licensing opportunities to enhance its R&D pipeline [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of the Lyme disease vaccine, with positive phase 3 results expected to be transformational for the company [22] - The company anticipates total product sales in 2026 to be between EUR 145 million and EUR 160 million, reflecting further planned reductions in third-party product sales [20] - Management emphasized the importance of cash management and reducing operating cash burn as key focuses moving forward [20] Other Important Information - Valneva achieved a more than 20% reduction in operating cash burn through disciplined cash management [5] - The company is investing in the further development of IXCHIQ and has initiated a pilot vaccination campaign in Brazil [10] Q&A Session Summary Question: When will Lyme data be available? - Management indicated that Pfizer controls the phase 3 study and expects data in the first half of 2026, with hopes for mid-H1 results [28] Question: What is the confidence level regarding VLA15's efficacy across different serotypes? - Management stated that preclinical models have shown promising results, but human data is still needed to confirm efficacy across serotypes [32] Question: What is the status of the DoD contract for IXIARO? - Management confirmed that a new contract is expected this year, and it is included in the revenue guidance for 2026 [63] Question: What are the criteria for ACIP recommendations for VLA15? - Management noted that ACIP recommendations depend on safety and efficacy data, with a focus on high-risk populations [44] Question: What are the next steps for IXCHIQ in Asia? - Management is evaluating potential partners and commercialization strategies for IXCHIQ in Asia, with announcements expected later this year [68]

Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [6] - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6] - Valneva's vaccine pipeline includes candidates for Lyme disease, Zika virus, and other global public health threats, with revenues from its commercial business supporting ongoing development [6] Chikungunya Vaccine Update - The UK’s Commission on Human Medicines (CHM) has updated its recommendations for Valneva's single-dose chikungunya vaccine, IXCHIQ, following a review of its benefits and risks [1] - The updated prescribing information includes restrictions for individuals over 60 years of age and those with specified health conditions, as well as guidelines on vaccination timing prior to travel [2] - The benefit-risk profile of IXCHIQ remains favorable for individuals aged 18 to 59 years who are at risk of chikungunya infection without contraindicated medical conditions [2][3] Safety Monitoring and Regulatory Actions - The update follows a temporary suspension of IXCHIQ's use in older individuals due to reports of serious adverse events primarily among elderly patients with significant underlying health conditions during a vaccination campaign [3] - Valneva is committed to maintaining high safety standards and will continue to monitor post-marketing safety data for IXCHIQ, collaborating with relevant authorities for potential updates to recommendations [4] Chikungunya Virus Context - Chikungunya virus (CHIKV) is a mosquito-borne disease causing severe joint pain, fever, and other symptoms, with significant global outbreaks since 2004 [5] - Over 3.7 million cases were reported in the Americas between 2013 and 2023, with the economic impact considered substantial, expected to grow due to climate change affecting mosquito distribution [5] - The World Health Organization (WHO) has identified chikungunya as a major public health problem, highlighting the need for effective vaccine solutions [5]

Core Viewpoint - Valneva SE has voluntarily withdrawn its biologics license application and Investigational New Drug application for its chikungunya vaccine, IXCHIQ, in the United States due to regulatory challenges and safety investigations [1][2]. Regulatory Actions - The U.S. FDA suspended the vaccine's license in August 2025, leading Valneva to await further guidance on its response [2]. - The FDA has placed the IND on clinical hold pending an investigation into a newly reported foreign Serious Adverse Event (SAE) [2]. Clinical Studies and Safety - Currently, no clinical studies involving IXCHIQ are actively vaccinating participants [3]. - Valneva intends to proceed with planned post-marketing clinical activities, subject to discussions with regulatory authorities [3]. Serious Adverse Event Investigation - The SAE under investigation occurred outside the U.S. and involved a younger adult who received three concomitant vaccines, including IXCHIQ [4]. - The case may be plausibly related to IXCHIQ vaccination, although causality has not been determined [4]. - The company is actively seeking additional details to further characterize the case [4]. Commitment to Safety - Valneva emphasizes its commitment to the highest safety standards and continues to engage proactively with authorities in all territories where IXCHIQ is licensed, including Europe, Canada, the United Kingdom, and Brazil [5]. Vaccine Target and Profile - IXCHIQ is targeted at travelers to regions where the chikungunya virus is endemic, such as tropical and subtropical areas in Asia, Africa, and the Americas [6]. - Valneva maintains that IXCHIQ's benefit-risk profile remains favorable for individuals living in endemic and outbreak settings, highlighting its unique positioning as a highly durable single-shot vaccine [6].

Core Viewpoint - Valneva SE has voluntarily withdrawn its biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ, in the U.S. following a suspension by the FDA due to safety concerns related to a Serious Adverse Event (SAE) [1][3][11] Company Summary - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [7] - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8] - Revenues from its commercial business support the advancement of its vaccine pipeline, which includes candidates for Lyme disease and Shigella, among others [9] Industry Context - Chikungunya virus (CHIKV) is a mosquito-borne disease that has caused significant outbreaks globally, with over 3.7 million cases reported in the Americas between 2013 and 2023 [6] - The World Health Organization (WHO) has identified chikungunya as a major public health problem, with the economic impact expected to grow due to climate change affecting the spread of mosquito vectors [6]

Core Insights - Valneva SE announced positive final antibody persistence and safety data for its Phase 2 clinical trial of the chikungunya vaccine IXCHIQ, showing promising results in 304 children twelve months post-vaccination [1][2][3] Vaccine Efficacy and Safety - The full dose of IXCHIQ elicited a 94.7% seroresponse rate in chikungunya virus-naïve children at Day 360, indicating a strong immune response [3][4] - The vaccine was well tolerated across all age groups tested, with no safety concerns identified [3][4][9] - The trial results align with previous data reported in January and June 2025, confirming the robustness of the immune response and safety profile [2][5] Future Development Plans - The company plans to initiate a Phase 3 study in children after gathering additional real-world experience in the adolescent population, emphasizing the importance of safety [5][9] - The selection of the full dose for future trials is supported by the favorable immune response and safety data observed [4][9] Chikungunya Context - Chikungunya has seen a significant rise in cases globally, with Brazil reporting over one million cases from January 2019 to July 2024, highlighting the urgent need for effective vaccination [5][7] - The World Health Organization has identified chikungunya as a major public health problem, with the disease affecting over 110 countries since its re-emergence [6][7] Trial Details - The Phase 2 trial (VLA1553-221) was a multi-center, randomized, observer-blinded study involving 304 healthy children aged one to eleven years, conducted in the Dominican Republic and Honduras [8][10] - Participants were randomized to receive either a full dose, a half dose, or an active control, with the primary focus on evaluating safety and immunogenicity [8][10]

Financial Data and Key Metrics Changes - Total revenues reached EUR 127 million for the nine months ended September 30, 2025, representing a growth of almost 9% compared to the same period in 2024 [4][16] - Product sales increased to EUR 119.4 million, up 6.2% from EUR 112 million in the first nine months of 2024 [14] - Operating loss reported at EUR 53.9 million compared to an operating profit of EUR 34.2 million in the prior year, primarily due to the sale of a priority review voucher in 2024 [18][19] Business Line Data and Key Metrics Changes - IXIARO sales increased by 12.5% to EUR 74.3 million, driven by sales to the U.S. Department of Defense and increased sales in Europe [14] - DUKORAL sales decreased from EUR 22.3 million to EUR 21.5 million, impacted by foreign currency fluctuations and a transition to a new distributor in Germany [14][15] - IXCHIQ sales surged to EUR 7.6 million from EUR 1.8 million, aided by the supply of doses during a chikungunya outbreak [15] Market Data and Key Metrics Changes - The gross margin on commercial products, excluding IXCHIQ, improved to 57.2% from 48.6% in the prior year, driven by better manufacturing performance [16] - IXIARO's gross margin reached 63.2%, up from 58.8%, while DUKORAL's gross margin improved to 52.3% from 34.8% [16] Company Strategy and Development Direction - The company aims to focus on strategic investments in R&D and anticipates continuous growth in product sales, particularly from the Lyme disease vaccine, VLA15, expected to be a significant growth driver [21][22] - Valneva is working on expanding IXCHIQ into low- and middle-income countries (LMICs) and is exploring new partnerships to enhance market access [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming Lyme vaccine data, which could lead to sustained profitability post-commercialization [21][22] - The company is focused on reducing cash burn and maintaining a strong cash position to support future growth initiatives [4][19] Other Important Information - The company successfully completed debt refinancing, enhancing financial flexibility [5] - Cash at the end of September 2025 was reported at EUR 143.5 million, down from EUR 168.4 million at the end of 2024 [19] Q&A Session Summary Question: Timeline for FDA response regarding IXCHIQ - Management indicated there is no predefined process for the FDA response and hopes for a collaborative interaction, although no specific timeline can be provided [29][30] Question: Impact of currency and distributor shift on DUKORAL - Management acknowledged currency impacts and noted a technical delay in sales due to the transition to a new distributor in Germany, expecting continued growth for DUKORAL [31][32] Question: Timing for Lyme phase III readout - Management stated that Pfizer controls the process and is taking steps to ensure timely results, with no major delays anticipated [36][38] Question: IXCHIQ BLA suspension and proposed remedies - The response to the FDA focused on medical evidence and a positive risk-benefit ratio, with ongoing pharmacovigilance reviews [40][41] Question: Launch timeline for VLA15 - Management confirmed that timelines communicated by Pfizer support a launch in the autumn of 2027, contingent on regulatory submission next year [46] Question: Future growth drivers for IXCHIQ - Management sees growth opportunities in travel and endemic countries, with ongoing discussions for market access in various territories [47][48] Question: Funding considerations for Zika vaccine candidate - Management highlighted uncertainties around funding and regulatory pathways, indicating that substantial funding would be necessary to proceed with development [54][55]

Financial Data and Key Metrics Changes - Total revenues reached EUR 127 million for the nine months ended September 30, 2025, representing a growth of almost 9% compared to EUR 112.5 million in the same period of 2024 [4][16] - Product sales increased to EUR 119.4 million, up 6.2% from EUR 112 million in the first nine months of 2024 [14] - Operating loss reported at EUR 53.9 million compared to an operating profit of EUR 34.2 million in the prior year, primarily due to the sale of a priority review voucher in the previous year [18] Business Line Data and Key Metrics Changes - IXIARO sales reached EUR 74.3 million, increasing 12.5% year-over-year, driven by sales to the U.S. Department of Defense and increased sales in some European countries [14] - Ducoral sales decreased from EUR 22.3 million to EUR 21.5 million, impacted by foreign currency fluctuations and lower sales during the transition to a new distributor in Germany [14][15] - Exchange sales significantly increased to EUR 7.6 million from EUR 1.8 million, including the supply of doses to combat a chikungunya outbreak [15] Market Data and Key Metrics Changes - The company is focusing on expanding into low- and middle-income countries (LMICs) and new territories for IXIARO, leveraging its differentiated product profile [20][21] - The Lyme disease vaccine, VLA15, is expected to be a major growth driver, with regulatory submissions anticipated in 2026 and a potential launch in autumn 2027 [20][31] Company Strategy and Development Direction - The company aims to achieve sustainable profitability post-approval and commercialization of the Lyme disease vaccine, which is seen as a significant growth catalyst [20][21] - Valneva is actively identifying new opportunities for its R&D pipeline, aiming to build a coherent strategy for future vaccine candidates [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming Lyme disease vaccine data, which is expected to be a pivotal moment for the company [20][37] - The company is focused on reducing cash burn and ensuring sufficient runway to reach key inflection points, with cash at September 30 reported at EUR 143.5 million [18][19] Other Important Information - The company successfully completed debt refinancing, enhancing financial flexibility [5] - Research and development expenses increased to EUR 59.7 million, partly due to costs related to the Shigella vaccine candidate [17] Q&A Session Summary Question: Timeline for FDA response regarding exchange - Management indicated there is no predefined process for the FDA response and hopes for a collaborative interaction [24][25] Question: Impact of currency and distributor shift on Ducoral sales - Management noted that the transition to a new distributor in Germany caused a technical delay in purchases, but growth for Ducoral is expected to continue [25][26] Question: Timing for Lyme phase 3 readout - Management stated that Pfizer controls the process and is taking steps to ensure an early readout, with no major delays anticipated [27][28] Question: Remedies proposed to FDA for exchange BLA suspension - The response to the FDA focused on medical evidence and positive risk-benefit ratios, with ongoing pharmacovigilance reviews [29] Question: Launch timeline for VLA15 - Management confirmed that timelines communicated by Pfizer support a launch in the autumn of 2027, contingent on regulatory submissions next year [30][31] Question: Funding considerations for Zika vaccine candidate - Management highlighted uncertainty around funding and regulatory pathways, indicating that substantial funding would be necessary to proceed with development [33][36]

Core Insights - Valneva SE reported consolidated financial results for the first nine months of 2025, showing total revenues of €127.0 million, an increase of 8.9% compared to €116.6 million in the same period of 2024 [2][10][17] - The company experienced a net loss of €65.2 million in the first nine months of 2025, contrasting with a net profit of €24.7 million in the same period of 2024, primarily due to the absence of one-time proceeds from the sale of a Priority Review Voucher [2][28] - Valneva's financial position was strengthened through successful debt refinancing, which improved financial terms and reduced operating cash burn [2][10] Financial Performance - Total revenues for the first nine months of 2025 were €127.0 million, up from €116.6 million in 2024, driven by product sales of €119.4 million, which increased by 6.2% from €112.5 million [2][18] - Adjusted EBITDA loss was €37.7 million in the first nine months of 2025, compared to a profit of €48.6 million in the same period of 2024, influenced by the previous year's one-time sale of the Priority Review Voucher [27][28] - Cash and cash equivalents stood at €143.5 million as of September 30, 2025, down from €168.3 million at the end of 2024 [32] Product Sales and Portfolio - Valneva's commercial portfolio includes three travel vaccines: IXIARO/JESPECT, DUKORAL, and IXCHIQ, with IXIARO/JESPECT sales increasing by 12.5% to €74.3 million in the first nine months of 2025 [3][6] - DUKORAL sales decreased slightly to €21.5 million, impacted by currency fluctuations and a transition in distribution to CSL Seqirus [7][20] - IXCHIQ sales rose significantly to €7.6 million, aided by supply for a chikungunya outbreak, although U.S. license suspension affected traveler segment sales [8][9] Research and Development - Valneva is advancing its Lyme disease vaccine candidate, VLA15, with the Phase 3 VALOR study on track, and results expected in the first half of 2026 [11][12] - The company is also developing a tetravalent Shigella vaccine candidate, S4V2, which has received Fast Track designation from the FDA, indicating its potential to address unmet medical needs [13][14] - Positive Phase 1 results were reported for the Zika vaccine candidate, VLA1601, although further development will depend on securing funding [15][16] Cost Management - Operating expenses were managed effectively, with research and development expenses increasing to €59.7 million, primarily due to costs associated with the Shigella vaccine candidate [22] - Marketing and distribution expenses decreased to €28.6 million, reflecting reduced advertising and promotional spending [23] - General and administrative expenses were reduced to €29.5 million, attributed to lower recruitment and insurance costs [24]